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 Three series of azole piperazine derivatives that mimic dicyclotyrosine (cYY), the 
natural substrate of the essential Mycobacterium tuberculosis cytochrome P450 
CYP121A1, were prepared and evaluated for binding affinity and inhibitory activity 
(MIC) against M. tuberculosis. Series A replaces one phenol group of cYY with a C3-
imidazole moiety, series B includes a keto group on the hydrocarbon chain preceding 
the series A imidazole, whilst series C explores replacing the keto group of the 
piperidone ring of cYY with a CH2-imidazole or CH2-triazole moiety to enhance 
binding interaction with the heme of CYP121A1. The series displayed moderate to 
weak type II binding affinity for CYP121A1, with the exception of series B 10a, 
which displayed mixed type I binding. Of the three series, series C imidazole 
derivatives showed the best, although modest, inhibitory activity against M. 
tuberculosis (17d MIC = 12.5 g/mL, 17a 50 g/mL). Crystal structures were 
determined for CYP121A1 bound to series A compounds 6a and 6b that show the 
imidazole groups positioned directly above the haem iron with binding between the 
haem iron and imidazole nitrogen of both compounds at a distance of 2.2 Å. A model 
generated from a 1.5 Å crystal structure of CYP121A1 in complex with compound 
10a showed different binding modes in agreement with the heterogeneous binding 
observed. Although the crystal structures of 6a and 6b would indicate binding with 
CYP121A1, the binding assays themselves did not allow confirmation of CYP121A1 
as the target. 
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1. Introduction 
Tuberculosis (TB) is an infectious, communicable bacterial disease, most 
commonly of the respiratory tract, usually caused by Mycobacterium tuberculosis 
(Mtb).1 Despite the 47% mortality rate reduction (1990-2014), case numbers are 
rising in developing countries with 1.8 million deaths from TB in 2015.2 An 
estimated 480,000 people developed multi-drug resistant TB (MDR-TB) in 2015.2 
The rise in MDR-TB, a form of TB caused by bacteria that do not respond to 
isoniazid and rifampicin,3 the two most effective first-line TB drugs, is alarming 
and highlights the need for the identification of new drug targets. 
 
Figure 1. Formation of mycocyclosin. M. tuberculosis CYP121A1 catalyses the oxidative 
crosslinking of the aryl side chains of the cyclic dipeptide, cyclo-L-Tyr-L-Tyr (cYY), to 
produce the novel secondary metabolite mycocyclosin. 
 
A potential new target is the cytochrome P450 enzyme CYP121A1 that was shown to 
be essential for mycobacterial growth through gene deletion and complementation 
studies.4 The natural substrate of CYP121A1 is the cyclic dipeptide (CDP) 
dicyclotyrosine (cYY) and it was found that CYP121A1 exhibits a novel 
diketopiperazine modifying activity, catalysing the formation of a C-C bond between 
the two tyrosyl side chains of cYY resulting in a novel chemical entity called 
mycocyclosin (Figure 1). The role of the secondary metabolite mycocylosin in M. 
tuberculosis remains unclear, although CDPs and their derivatives have important 
biological effects, including (i) cFP in the bacterial pathogen Vibrio cholerae, 
production of which inhibits production of bacterial virulence factors, (ii) cLY which 
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can inhibit biofilm formation in the skin bacterium Staphylococcus epidermidis; and 
cHP which has reported neuroprotective effects in mammals.5-7 
Recent studies revealed that only cyclodipeptides with a diketopiperazine ring and 
two aryl side chains with L-configuration bound well to CYP121A1, and that only 
cYY itself was efficiently transformed to a product.8,9 
The binding of cYY to CYP121A1 includes a direct hydrogen bond interaction 
between the carbonyl of cYY and the side chain nitrogen of Asn85, and a water-
mediated hydrogen bonding pattern. Hydrophobic interactions are demonstrated on 
the other side chain (Figure 2). The CDP cYY is a small molecule that partially 
occupies (300 Å) the large active site cavity (1350 Å3) of CYP121A1, and makes 
several interactions with P450 amino acids, both directly and via interstitial active site 
water molecules.9 
 
Figure 2. Crystal structure of cYY bound to CYP121A1. cYY is shown with carbon atoms in 
yellow, and with interactions between cYY and active site amino acids and water molecules 
shown with dotted lines. cYY shows indirect binding coordination of the CYP121A1 heme 
iron through an axial water molecule (red) to the heme iron (cyan) (pdb code: 3G5H). 
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Three small series that mimic the natural substrate cYY have been developed (Figure 
3). Series A replaces one of the phenol rings of cYY, which is positioned directly 
above the heme group in the crystal structure (Figure 2), for a C3-imidazole. Flexible 
alignment showed that the three carbon chain allowed optimal overlap of the 
imidazole ring with the phenol ring (Figure 3). Also in this series, the central 




Series B flexible alignment 
 
Series C flexible alignment 
 
Series A flexible alignment 
 
 
Figure 3. Designed cYY mimics from series A, B and C. Flexible alignment of cYY (yellow) 
with series A (cyan), series B (orange) and series C (magenta). 
 
Series B includes a keto group on the hydrocarbon chain preceding the series A 
imidazole. The rationale for this modification of series B was to mimic the piperazine 
keto group, and the shorter two carbon chain, attached to a piperidine ring with more 
conformational flexibility, that was a sufficient length to allow overlap of the 
imidazole with the phenol ring (Figure 3). Series 3 is perhaps the closest mimic 
retaining two aromatic rings, although it has the piperazine ring with more 
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conformational flexibility, as with series B. In Series C the keto group of the 
piperidone ring of cYY is replaced by a CH2-imidazole or CH2-triazole, to determine 
whether a direct interaction between the inhibitor compound and the heme group 
might place the inhibitor more optimally within the active site.  
The choice of imidazole and triazole as the haem-binding heterocycles was based on 
previous binding studies,10,11 which showed that the imidazole interacts optimally 
through a N:-FeIII-haem coordinate link, through the N3 of imidazole, while 
introducing an additional nitrogen in the heterocyclic ring (triazole) reduces the 
coordination potential through the N: due to the electron withdrawing effect of the 
additional electronegative nitrogen. This effect is further increased with two 
additional nitrogens (tetrazole) drawing electron density from both sides of the 
coordinating nitrogen. Although the triazole is expected to have a lower binding 
affinity for the haem iron, the lower basicity of the triazole can confer greater 
isoform-specific selectivity in various CYP enzymes.12 
2. Results and discussion 
2.1 Chemistry  
Series A began with the preparation of the 4-(substituted)-3-oxo-piperazine-1-
carboxylic acid tert-butyl esters (3) according to the literature procedure13 by addition 
of the substituted benzyl chlorides (1) to a solution of 1-Boc-3-oxopiperazine (2) in 
anhydrous DMF in the presence of NaH (Scheme 1). Deprotection of the Boc 
protecting group of (3) was achieved using 4 M HCl solution in dioxane to obtain the 
piperazine (4) in very good yields.  Treatment of 1-(substituted)-piperazin-2-one (4) 
with K2CO3 and dibromopropane for 48 h gave the alkylated products (5) after 
purification by flash column chromatography.14 Reaction of 4-(bromopropyl)-1-(4-
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substituted-benzyl)-piperazin-2-ones (5) with the sodium salt of imidazole gave the 
final imidazole products (6) in moderate yields (Scheme 1). 
 
Scheme 1. Reagents and conditions: (i) NaH, DMF, 70 oC, o/n (ii) 4 M HCl, dioxane, o/n (iii) 
K2CO3, acetone, Br(CH2)3Br, 48 h (iv) imidazole, NaH, DMF, 45 oC, o/n. [a, R = 4-F; b, R = 
4-Cl; c, R= 4-OCH3; d, R = 2,4-diCl] 
 
Series B began with the preparation of 1-(substituted-benzyl)piperazine (8) by 
addition of substituted benzyl chloride (1) to a solution of excess piperazine (7) in 
anhydrous THF. Treatment of the formed 1-(substituted-benzyl)piperazine (8) with 
triethylamine and 2-chloroacetyl chloride gave the acylated products (9),15 which 
were pure enough to proceed for the next step. The final compounds (10) were 
prepared by reaction of the acylated products (9) with 1,2,4-triazole or imidazole in 
the presence of K2CO3 (Scheme 2). 
 
Scheme 2. Reagents and conditions: (i) THF, 70 oC, 2.5 h (ii) 2-chloroacetylchloride, Et3N, 
0oC, 2 h then rt 5 h (iii) K2CO3, CH3CN, imidazole or triazole, 45 oC, 1 h then 9, 70 oC, o/n. 
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For Series C the substitutions were limited to unsubstituted and methoxy groups. The 
methoxy substituents were included as H-bond acceptors to mimic the phenolic 
hydroxyl of the tyrosine group of cYY. The imines (12) were prepared by reaction of 
ethylenediamine and the desired benzaldehyde (11) in ethanol overnight at room 
temperature (Scheme 3). Subsequent reduction of the imines (12)16 with NaBH4 gave 
the diamines (13)17, which on reaction with 2,3-dibromopropionic acid ethyl ester and 
triethylamine in toluene at 80 °C resulted in cyclisation to the piperazine esters (14). 
Ester reduction was performed using LiAlH4 giving the corresponding alcohols (15). 
The unsubstituted and 4-methoxy derivatives 15a and 15b were then converted to the 
chlorides (16a and 16b) on reaction with thionyl chloride at reflux overnight. 
Attempts to convert the dimethoxy alcohol (15c) to the chloride were unsuccessful 
with a complex reaction mixture obtained, and therefore the dimethoxy alcohol (15c) 
was first converted to the mesylate intermediate by reaction with methanesulphonyl 
chloride in the presence of base (Et3N). Treatment of the chlorides and mesylate with 
either the sodium salt of imidazole or triazole generated in situ on reaction of 
imidazole and triazole, respectively, with NaH in acetonitrile or toluene, gave the 
final imidazole and triazole compounds (17) (Scheme 3).  
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Scheme 3. Reagents and conditions: (i) H2NCH2CH2NH2, EtOH, o/n (ii) NaBH4, MeOH, o/n 
(iii) 2,3-dibromopropionic acid ethyl ester, toluene, Et3N, 80 oC, o/n (iv) LiAlH4, Et2O, o/n 
(v) SOCl2, toluene, 115 oC, o/n (vi) NaH, imidazole or triazole, CH3CN, 80 oC, o/n (vii) 
MsCl, Et3N, CH2Cl2, 4 h (vii) NaH, imidazole, toluene, 115 oC, o/n. [a, R = H, X =CH; b, R = 
H, X = N; c, R= 4-OCH3, X = N; d, R = 3,5-diOCH3, X = CH] 
 
2.2 Binding affinity  
UV–visible absorption spectroscopy is an important technique for the characterization 
and quantification of cytochrome P450 enzymes, including the assessment of whether 
an applied ligand is a likely substrate or inhibitor, based on it causing a heme Soret 
band blue or red shift, respectively. The oxidized form of pure CYP121A1 shows 
spectral properties that are similar to those of many other predominantly low-spin 
P450 enzymes, with the major (Soret or ) ferric heme band located at 416 nm (most 
P450s have the low-spin Soret feature at ~418-419 nm), and the smaller  and  
bands at 565 and 538 nm, respectively. On reduction of CYP121A1 with sodium 
dithionite and binding of carbon monoxide at basic pH, the Soret band shifts to 448 
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nm with a small decrease in intensity, confirming that cysteine thiolate coordination is 
retained in the FeII-CO state (Figure 4).18 
 
 
Figure 4: Spectroscopic characteristics of CYP121A1. CYP121A1 (solid line, 5.2 M) in the 
normal low-spin resting form with Soret peak at 416nm and  and  bands at 565 and 538 
nm, respectively. CYP121A1 retains a small degree of high-spin with a charge transfer band 
at 649 nm and small Soret shoulder at 394 nm. Reduction with sodium dithionite (dotted line) 
shows a decrease in intensity of the Soret peak and shift to 406 nm with fusion of the  and  
bands to a new peak at 547nm. Addition of carbon monoxide to reduced CYP121A1 shows 
the characteristic ‘P450’ peak at 448 nm. 
 
Binding titrations were carried out for compounds 6 (series A), 10 (series B) and 17 
(series C). Results shown in Table 1 revealed that compounds from series A, B and C 
produce small spectral changes and produce moderate to high dissociation constants 
using either a hyperbolic fit or the Hill function in cases where the data were 
sigmoidal in nature. Addition of all the compounds (with the exception of 10a) 
showed a type II (inhibitor-like) red shift in the heme Soret peak to a longer 
wavelength, indicating binding of the azole (or triazole) nitrogen to the heme iron 
(Figure 5). Series A displays the tightest binding with lowest Kd values determined in 
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particular for the halogenated compound 6b (4-Cl group, Kd = 81.3 ± 2.9 M) and 
compound 6a (4-F group, Kd = 225.8 ± 2.6 M). Interestingly, the triazole-containing 
2-4-dichloro derivative compound 10a displays a heterogeneity in binding mode with 
the development of a blue-shifted high spin type I (substrate-like) shoulder at 393 nm 
that is accompanied by the appearance of a small charge transfer species at 648 nm, 
which is also associated with substrate-like binding. In contrast, the remaining Series 
B and C compounds display small type II inhibitor like spectral changes upon binding 
to CYP121A1 (Figure 5). The binding of compounds 6b, 6c and 10a to CYP121A1 
was best fitted using the Hill function. The apparent cooperative nature of the binding 
of these ligands may suggest that more than one molecule of these compounds can 
enter the CYP121A1 active site, or e.g. that there are interactions between CYP121A1 
proteins that influence binding affinity. Such phenomena are relatively common in 










Figure 5. CYP121A1 titrations with selected novel ligands. (A) Spectral titration data for 
CYP121A1 with various ligands designed and synthesized in this study. Most ligands 
produce a type II spectral shift indicative of direct or indirect (e.g. via H2O molecule(s)) 
interactions of these ligands with the P450 heme iron. The exception shown here is molecule 
10a, which induces a type I spectral change indicative of substrate-like P450 behaviour. (B) 
Data plots for each ligand, fitted using either hyperbolic (Michaelis-Menten) or sigmoidal 
(Hill) functions. Data for compound 6a were best fitted using the hyperbolic function, while 
data for compounds 6b, 6c and 10a were fitted using the Hill function.  
 
 
Azole antifungal drugs (clotrimazole, econazole, fluconazole, ketoconazole 
and miconazole) were found to bind tightly to Mtb CYP121A1 inducing a shift of the 
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soret peak to 423.5 nm. The Kd values for clotrimazole, econazole and miconazole are 
< 0.2 μM indicating tight binding. Fluconazole a triazole compound, showed weaker 
binding with a Kd value 8.6 ± 0.2 μM, while the imidazole-containing clotrimazole 
showed much higher affinity than fluconazole with a Kd value of 0.07 ± 0.01 μM, as 
determined from a fit to the Morrison equation (Table 1).18 The natural substrate cYY 
has a Kd value of 5.82 ± 0.16 μM.  
 
Table 1.  Kd, MIC data and calculated LogP for series A and series B 
Compound R X Kd (M) MIC90 
(g/mL) 
cLogPa 
6a 4-F - 225.8 ± 2.6 >100 1.19 
6b  4-Cl - 81.3 ± 2.9 >100 1.59 
6c  4-OCH3 - 308.9 ± 21.8 >100 0.91 
6d  2,4-diCl - 967.1 ± 41.3 100 2.15 
10a 2,4-diCl N 417 ± 39 >100 1.63 
10b 4-F N 960 ± 62 >100 1.33 
10c 4-F CH 1142 ± 144 >100 1.88 
17a H CH 1968 ± 137 50 3.56 
17b H N 1834 ± 62 >100 3.06 
17c  4-OCH3 N 1298 ± 124 100 2.81 
17d 3,5-diOCH3 CH 1435 ± 94 12.5 3.05 
Fluconazole15 - - 8.6 ± 0.2 >100 0.87 
Clotrimazole15  - - 0.07 ± 0.01 0.1 5.97 
cYY - - 5.82 ± 0.16 
 
- 1.26 
a. Crippen's fragmentation21 
 
2.3 EPR spectroscopy of ligand binding to CYP121A1 
X-band EPR spectroscopy provides important information on P450 heme iron 
coordination environment and any heterogeneity therein. EPR studies were done for 
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CYP121A1 in the ligand-free state and in complex with the compounds from series 
A, B and C.  
 
Table 2. X-band EPR spectra of CYP121A1 in its ligand-free form and for complexes with 
ligands from series A, B and C.  
CYP121A1 
ligand/additive 
High-spin (HS)   
g-values 
Low-spin (LS) g-values % HS 
No additive 7.94, 3.59 2.49, 2.25, 1.89 2.5 
DMSO 7.94, 3.58 2.49, 2.25, 1.89 2.5 
6a 7.94, 3.48 2.46, 2.26, 1.90 1.2 
6b 7.94, 3.43 2.46, 2.26, 1.90 1.3 
6c 7.96 2.47, 2.26, 1.90 1.2 
6d 7.97 2.45, 2.26, 1.90 1.2 
10a 7.92, 3.61, 1.70 2.47 (sh. 2.41), 2.26, 1.90 22 
10b 7.96, 3.51 2.47, 2.26, 1.90 1.3 
10c 7.96, 3.48 2.47, 2.26, 1.89 1.2 
17a 7.95, 3.58 2.47, 2.26, 1.89 1.2 
17b 7.96, 3.54 2.47, 2.26, 1.89 1.3 
17c 7.95, 3.52 2.47, 2.26, 1.90 1.1 
17d 7.95, 3.44 2.47, 2.26, 1.90 1.1 
cYY 8.05, 3.44 2.46, 2.25, 1.90 2.9 
Fluconazole 7.94, 3.58 2.45, 2.26, 1.90 2.5 
The g-values for the LS and HS forms of CYP121A1 are indicated in each case with the 
percentage high-spin (HS) in each sample calculated from integration of the spectral peaks. 
The g-values are given as gz/gy/gx for both the LS and HS components. The HS gx signal is 
too weak to be resolved clearly in most samples. The low intensity of the gy signal also 
precludes its accurate positioning in the case of compounds 6c and 6d. The “sh.” in the case 
of compound 10a indicates a shoulder feature at gz = 2.41 on the main gz value at 2.47. 
 
Ligand-free CYP121A1 has a major rhombic LS spectrum with g-values at 2.49 (gz), 
2.25 (gy) and 1.85 (gx) (2.49/2.25/1.85), consistent with a dominant axial coordination 
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state from cysteine thiolate (proximal) and water (distal) ligands. In addition to the LS 
signal, there is a small proportion of HS heme retained in CYP121A1, with g-values 
at 7.94 and 3.59 (Table 2, Figure 6). This small HS signal is consistent with the native 
CYP121A1 UV-Vis spectrum (Figure 4). EPR analyses of CYP121A1 in complex 
with the compounds, with the exception of the series B compound 10a, revealed 
subtle perturbations in the EPR spectrum, with ~50% decreases in the HS spectral 
component and a slight narrowing of the LS signal with g-values of the 
2.46(2.47)/2.26/1.90 (c.f. cYY 2.46, 2.25, 1.90)8.  
 
Figure 6. X-band EPR spectra for CYP121A1 in the ligand-free form and when bound to 
compounds 6a and 10a. The g-values are indicated for each peak with HS signals labelled 
with an asterisk. 
These results are not immediately indicative of direct coordination of the heme iron 
by nitrogen atoms in these molecules, although indirect ligation (via H2O 
molecule(s)) cannot be ruled out. In contrast, the addition of compound 10a displayed 
a significant perturbation of the EPR spectrum with a 9-fold increase in the amount of 
HS ferric heme iron (Table 2). A small degree of heterogeneity in the LS signal was 
also observed, with the formation of a shoulder in the LS gz signal at 2.41 suggesting 
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a different binding mode for this ligand in the CYP121A1 active site. Selected EPR 
spectra are shown in Figure 6.  
 
2.4 Antimycobacterial assay  
The derivatives of series A, B and C were screened against Mtb H37Rv by the REMA 
(Resazurin Microtiter Assay) method.20 In series A only compound 6d displayed 
inhibitory activity against M. tuberculosis (Table 1) and compounds from Series B 
were inactive (all >100 g/mL). Series C was more promising with inhibitory activity 
observed for three of the derivatives, and with notable activity for the imidazole 
derivatives 17a and 17d (50 and 12.5 g/mL respectively). There would appear to be 
a correlation between lipophilicity (cLogP, Table 1) and antimycobacterial activity, 
which might be explained by enhanced uptake across the lipid dense outer 
mycobacterial cell wall. 
 
2.5 Crystallography and Molecular Modelling  
The structures of CYP121A1 in complex with compounds 6a and 6b were solved to 
1.64 and 1.5 Å, respectively (PDB codes 5O4L and 5O4K) (Table 3). Compound 6a 
and 6b both sit in a very similar position within the CYP121A1 active site with the 
imidazole nitrogen coordinated to the heme iron at a distance of 2.2 Å in both cases 
(Figure 6). A direct H-bond interaction between the keto group of the piperazine ring 
and Asn85 is observed. In addition, water-bridged H-bonds are formed between the 
protonated piperazine amine and Met62, Val82 and Val83, and between the 
piperazine ring and propyl chain linker and Ala233, Gln385 and Arg386.  The 
observed interactions of 6a and 6b closely mimic the interactions observed with cYY 
binding (Figure 2). 
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Table 3. X-ray crystallography data collection and final structural refinement statistics for 
CYP121A1 in complex with compounds 6a and 6b. 
Data Collection and 
Refinementa 
CYP121A1/6a complex 
PDB ID 5O4L 
CYP121A1/6b complex  
PDB ID 5O4K 
Data Collection   
Wavelength (Å) 0.9795 0.9795 
Space group P6522 P6522 
Cell dimensions  
     a, b, c (Å)  
     α, β, γ (°)  
 
77.53, 77.53, 264.95 
90.0, 90.0, 120.0 
 
77.625, 77.625, 264.291 
90.0, 90.0, 120.0 
Resolution (Å)  65.09  - 1.64 (1.70  - 1.64) 47.12  - 1.5 (1.56  - 1.5) 
Unique reflections 58784 (5714) 76451 (7498) 
Multiplicity 19 (20) 19 (20) 
Completeness (%) 100 (100) 100 (100) 
Mean I/sigma(I) 12.5(1.7) 18.1 (3.0) 
Wilson B-factor (Å2) 20.3 16.1 
R-merge 16.9 11.1 
R-meas 17.7 11.5 
R-pim 4.1 2.6 
Refinement   
CC1/2 0.99 (0.49) 0.99 (0.91) 
No. Reflections (unique) 58784 (5714) 76444 (7497) 
No. Reflections (R-free) 2000 (195) 1993 (195) 
R-work 0.18 (0.33) 0.16 (0.24) 
R-free 0.20 (0.34) 0.19 (0.26) 
No. non-hydrogen atoms 3588 3719 
     macromolecules 3115 3128 
     ligands 71 81 
     solvent 402 510 
Protein residues 394 394 
RMS(bonds) 0.016 0.019 
RMS(angles) 1.66 1.92 
Ramachandran favored (%) 99 99 
Ramachandran allowed (%) 0.5 0.98 
Ramachandran outliers (%) 0 0 
Rotamer outliers (%) 0.87 1.8 
Clashscore 3.11 3.24 
Average B-factor 23.93 20 
     macromolecules 22.66 18.32 
     ligands 25.95 21.99 
     solvent 33.39 30 
No. TLS groups 1 1 








Figure 6. X-ray crystal structures and electron density maps of (a) 6a and (b) 6b binding to 
CYP121A1.  
 
A 1.5 Å crystal structure of CYP121A1 in complex with compound 10a was obtained. 
However, incomplete ligand occupancy prevented adequate refinement of the 
structure. Analysis of the ligand density of compound 10a suggests that it likely 
acquires different binding orientations with two major conformations being rotated 
around the substituted piperazine central moiety of the ligand. In both orientations the 
imidazole groups are located pointing away from the heme towards the top of the 
active site cavity. In one orientation the 4-chloro group is situated 3.1 Å from the 
heme iron and is sandwiched between the active site residues Ser237 and Ala233 
(Figure 7). In contrast, the same 4-chloro group in the second ligand orientation is 
11.6 Å away from the iron and rotated 35.2 degrees from the former orientation with 
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respect to the heme iron (Figure 7). For this second orientation, the 2-4-
dichlorobenzene ring stacks with the aromatic Phe168 residue that interacts with the 
one of the tyrosyls of the natural substrate cYY. The different orientations of 
compounds 10a and the proximity of the halogen (4-Cl group) to the heme iron are in 
agreement with the UV-vis spectral data observed that reflect different binding modes 
and a degree of high-spin (HS) species present. 
 
 
Binding mode 1 (cyan structure) Binding mode 2 (magenta structure) 
 
 
Figure 7. Multiple binding modes for compound 10a in its complex with CYP121A1.   
 
Flexible alignment of series C with cYY as shown in Table 4 (17 (grey), natural 
substrate cYY (yellow)), indicated the overlap of the cYY tyrosyl groups with the two 
aromatic moieties. The cYY ketopiperazine ring is overlapped with the piperazine, 
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while the imidazole and triazole rings are placed in the same position of the cYY 
carbonyl group, but at a longer distance where they act as hydrogen bond acceptors. 
The score of alignment is shown in Table 4 with compound 17c showing the best 
score (Table 4). 
 





Compound R X Score (Kcal/mol) 
17a H CH -21.99 
17b H N -36.39 
17c OCH3 N -38.30 
17d 3,5-dimethoxy CH -19.44 
 
From docking studies using MOE (Molecular Operating Environment) software22 it 
appeared that the orientation of the Series C piperazine derivatives (S- and R-
enantiomers) in the CYP121A1 active site may allow the formation of a transition 
metal interaction directly between the nitrogen atom of the imidazole or triazole and 
the heme iron, as the distance was less than 3 Å. Hydrophobic interactions made by 
the series C compounds included those with Phe280, Ser237, Ala233, Pro285 and 
Thr77, which are key amino acids that interact with the natural substrate cYY (Figure 
8). However, binding studies would suggest indirect binding to the heme via a water 




Figure 8. Docking of the Series C piperazine derivative (S)-17c into the CYP121A1 active 
site showing the distance (2.55 Å) between the triazole nitrogen and the haem iron. 
 
3. Conclusions 
A series of novel ligands were developed as potential inhibitors of the Mtb P450 
enzyme CYP121A1 (Figure 3). These molecules are structural mimics of the natural 
cYY substrate, but to which a heme iron-coordinating imidazole or triazole group are 
appended in different positions on the scaffold, with other functional groups also 
introduced in place of the hydroxyl group(s) in cYY. For series A, crystallography 
would indicate a direct binding interaction with the haem iron. However, this does not 
translate to strong binding affinity. It could be that the structures are just locked in a 
‘bound’ orientation that favors their structural solution, whereas in solution they are 
more mobile as indicated by the small spectral changes observed in the UV-Vis 
spectrum. In series B compound 10a showed a distinct type I binding mode (Figure 5) 
further supported by a significant perturbation of the EPR spectrum with a 9-fold 
increase in the amount of HS ferric heme iron (Table 2, Figure 6). Further 
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development of series C molecules is warranted based on their inhibitory activity 
against Mtb (Table 1). While CYP121A1 optical binding assays do not show 
significant perturbation of the heme spectrum, this may be due to the series C 
inhibitors binding in an orientation that does not influence the heme axial 
coordination environment. However, at present we cannot conclude definitively that 
the activity against Mtb results from inhibition of CYP121A1. Binding affinity in the 
low M range against CYP121A1 has been reported by Fonvielle et al9 for cYY 
derivatives and by Hudson et al23,24 for small fragment heterocyclic inhibitors. 
However, no inhibitory activity (i.e. MIC values) against Mtb has been reported, and 
so it is unknown whether the binding affinity would translate to a potent MIC value. 
Similarly, the antifungal azole fluconazole shows good CYP121A1 binding affinity, 
but no Mtb inhibitory activity25 (although other azole drugs, e.g. econazole, do 
possess anti-Mtb activity).18 There are 20 different P450 isoforms encoded within the 
M. tuberculosis genome,26 a number of which are considered important for 
pathogenicity and survival in the host, and these P450s could provide novel drug 
targets against pathogenic mycobacteria. The synthesis of CYP121A1 inhibitors is 
still in its infancy and, with the exact physiological role of this enzyme still to be 
determined, the development of selective inhibitors will be important for the analysis 
of CYP121A1 mechanism, as well as being potential leads for new antibiotics that 
target cytochrome P450 monooxygenase chemistry in Mtb. 
 
4. Experimental 
4.1 General Experimental 
All chemicals, reagents and solvents were purchased from Sigma-Aldrich and Fisher 
Scientific companies and the required solvents were dried and stored over 
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4 Å molecular sieves under nitrogen. Flash column chromatography was performed 
with silica gel 60 (Merck 40–60 nm, 230–400 mesh) and TLC was performed on 
precoated silica gel plates (Merck Kiesegel 60 F254) with visualization via UV light 
(254 nm) and / or vanillin stain. Melting points were determined on an electrothermal 
instrument (Gallenkamp) and are uncorrected. Compounds were visualized by 
irradiation with UV light at 250 nm and 366 nm. 1H and 13C-NMR spectra were 
recorded on a Bruker Advance DPX500 spectrometer operating at 500 MHz and 125 
MHz. Mass spectra (LRMS and HRMS) were determined under EI (Electron Impact) 
or CI (Chemical Ionization) conditions at the EPSRC National Mass Spectrometry 
Service Centre, University of Wales, Swansea, or at the Department of Chemistry, 
University of Wales, Cardiff. Microanalysis data were performed by Medac Ltd., 
Brunel Science Centre, Surrey. The chloroacetyl derivatives (9) imines (12) and 
diamines (13) were prepared as previously described.15-17 
4.2 Chemistry 
4.2.1. General method for the synthesis of 1-Boc- 4-(substituted)-3-oxopiperazine 
(3) 
To a solution of 1-Boc-3-oxopiperazine (2) (0.5 g, 2.49 mmol) in anhydrous DMF (10 
mL) was added NaH (60% dispersion in mineral oil) (0.08 g, 3.7 mmol). The reaction 
was stirred at room temperature for 2 h then substituted benzyl chloride (1) (2.99 
mmol) was added and the reaction heated at 70 °C overnight. The reaction mixture 
was cooled in an ice bath, quenched with water (5 mL) and then evaporated under 
reduced pressure. The product was extracted with ethyl acetate (100 mL) and washed 
with water (3 x 50 mL). The organic layer was dried (MgSO4), evaporated under 
reduced pressure and the residue purified by flash chromatography using 
CH2Cl2:CH3OH gradient elution unless stated otherwise. 
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4.2.1.1. tert-Butyl 4-(4-fluorobenzyl)-3-oxopiperazine-1-carboxylate (3a)13 
Synthesised using 1-chloromethyl-4-fluorobenzene (0.43 g, 2.9 mmol). Yield: 63% as 
a white solid, m.p: 86-92 °C. 1H-NMR (CDCl3): δ 7.20 (m, 2H, Ar), 7.03 (m, 2H, Ar), 
4.59 (s, 2H, CH2), 4.10 (s, 2H, CH2), 3.60 (t, J = 5.5 Hz, 2H, CH2), 3.27 (t, J = 5.5 Hz, 
2H, CH2), 1.17 (s, 9H, t-Bu). 
13C-NMR (CDCl3): δ 165.8 (C=O, piperazine), 163.4, 
161.4 (C-F), 153.8 (C=O), 132.1 (C), 132.05 (2 x CH, Ar), 115.7 (2 x CH, Ar), 80.9 
(C, t-Bu), 49.3 (2 x CH2), 45.6 (2 x CH2), 28.6 (3 x CH3, t-Bu). 
4.2.1.2. tert-Butyl 4-(4-chlorobenzyl)-3-oxopiperazine-1-carboxylate (3b) 
Synthesised according to the general procedure using 4-chlorobenzylchloride (0.48 g, 
2.9 mmol) the residue was purified by flash chromatography using petroleum ether: 
EtOAc, the product was collected at 40:60 v/v. Yield: 41% as a white solid, m.p: 80-
82 °C. 1H-NMR  (CDCl3): δ 7.32  (d, J = 8.4 Hz, 2H, Ar), 7.22  (d, J = 8.4 Hz, 2H, 
Ar), 4.59 (s, 2H, CH2), 4.16  (s, 2H, CH2), 3.60  (t, J = 5.4 Hz, 2H, CH2), 3.26  (t, J = 
5.2 Hz, 2H, CH2), 1.48  (s, 9H, t-Bu). 
13C-NMR (CDCl3): δ 164.8 (C=O, piperazine), 
153.8 (C=O), 134.8 (C), 133.7 (C), 129.6 (2 x CH, Ar), 129.0 (2 x CH), 80.9 (C, t-
Bu), 49.5 (2 x CH2), 45.7 (2 x CH2), 28.3 (3 x CH3, t-Bu). Anal. Calcd for 
C16H21ClN2O3 (324.80): C, 59.17; H, 6.52; N, 8.62. Found: C, 59.15; H, 6.43; N, 
8.38. 
4.2.1.3. tert-Butyl 4-(4-methoxybenzyl)-3-oxopiperazine-1-carboxylate (3c) 
Synthesised using 4-methoxybenzylchloride (0.46 g, 2.9 mmol). Yield: 74% as a 
white solid, m.p: 96-98 °C. 1H-NMR (CDCl3): δ 7.2 (d, J = 8.6 Hz, 2H, Ar), 6.87 (d, J 
= 8.5 Hz, 2H, Ar), 4.56 (s, 2H, CH2), 4.14 (s, 2H, CH2), 3.8 (s, 3H, CH3), 3.57 (t, J = 
5.4 Hz, 2H, CH2), 3.24 (t, J = 5.4 Hz, 2H, CH2), 1.40 (s, 9H, t-Bu). 
13C-NMR 
(CDCl3): δ 165.6 (C=O, piperazine), 162.5 (C), 153.8 (C=O), 129.7 (2 x CH, Ar), 
128.6 (C), 114.1 (2 x CH, Ar), 80.7 (C, t-Bu), 55.3 (CH3), 49.3 (2 x CH2), 45.3 (2 x 
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CH), 28.3 (3 x CH3, t-Bu). Anal. Calcd for C17H24N2O4 (320.38): C, 63.73; H, 7.55; 
N, 8.70. Found: C, 63.48; H, 7.60; N, 8.60. 
4.2.1.4. tert-Butyl-4-(2,4-dichlorobenzyl)-3-oxopiperazine-1-carboxylate (3d) 
Synthesised according to the general procedure using 2,4-dichloro-1-
(chloromethyl)benzene (0.58 g, 2.9 mmol), the residue was purified by flash 
chromatography using  petroleum ether: EtOAc, the product was collected at 40:60 
v/v. Yield: 85 % as a cream solid, m.p: 98-106 °C. 1H-NMR (CDCl3): δ 7.42   (d, J = 
1.7 Hz, 1H, Ar), 7.26 (m, 2H, Ar), 4.75 (s, 2H, CH2), 4.15 (s, 2H, CH2), 3.64 (t, J = 
5.4 Hz, 2H, CH2), 3.33 (t, J = 5.4 Hz, 2H, CH2), 1.49 (s, 9H, t-Bu). 
13C-NMR 
(CDCl3): δ 166.1 (C=O, piperazine), 153.8 (C=O), 134.4 (C), 134.2 (C), 132.4 (C), 
130.7 (CH, Ar), 129.5 (CH, Ar), 127.66 (CH, Ar), 81.0 (C, t-Bu), 46.3 (2 x CH2), 46.9 
(2 x CH2), 28.3 (3x CH3, t-Bu). Anal. Calcd for C16H20Cl2N2O3 (359.25): C, 53.49; H, 
5.61; N, 7.99. Found: C, 53.62; H, 5.59; N, 7.70. 
4.2.2. General method for the synthesis of 1-(substituted)-piperazin-2-ones (4)  
To the N-Boc-protected amine (3) (2 mmol) was added to a HCl solution (4M in 
dioxane, 33 mL). The reaction was stirred overnight at room temperature then 4M 
aqueous NaOH was added until alkaline. The solution was extracted with ethyl 
acetate (4 x 50 mL) then the organic layers combined, dried (MgSO4) and evaporated 
under reduced pressure. The product was pure enough for use in the next step.  
4.2.2.1. 1-(4-Fluorobenzyl)-piperazin-2-one (4a) 
Synthesised according to the general procedure using tert-butyl 4-(4-fluorobenzyl)-3-
oxopiperazine-1-carboxylate 3a (0.47 g, 1.52 mmol). Yield: 74% as a pale yellow oil. 
1H-NMR (CDCl3): δ 7.21 (m, 2H, Ar), 7.02 (m, 2H, Ar), 4.57 (s, 2H, CH2), 3.50 (s, 
2H, CH2), 3.22 (t, J = 5.5 Hz, 2H, CH2), 3.04 (t. J = 5.5 Hz, 2H, CH2), 1.92 (br.s, 1H, 
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NH). 13C-NMR (CDCl3): δ 167.8 (C=O), 163.3 (C-F), 161.3 (C-F), 132.5 (C), 129.9 
(2 x CH, Ar), 115.6 (2 x CH, Ar), 50.3 (CH2), 49.2 (CH2), 47.2 (CH2), 43.2 (CH2).  
4.2.2.2. 1-(4-Chlorobenzyl)-piperazin-2-one (4b) 
Synthesised according to the general procedure using 4-(4-chlorobenzyl)-3-oxo-
piperazine-1-carboxylic acid tert-butyl ester 3b (0.33 g, 1.02 mmol). Yield: 74% as a 
pale yellow solid, m.p: 49-50 °C. 1H-NMR (CDCl3): δ 7.29 (d, J = 6.9 Hz, 2H, Ar), 
7.20 (d, J = 7.1 Hz, 2H, Ar), 4.56 (s, 2H, CH2), 3.58 (s, 2H, CH2), 3.21 (t, J = 5.2 Hz, 
2H, CH2), 3.03 (t, J = 5.2, 2H, CH2), 1.97 (br.s, 1H, NH). 
13C-NMR (CDCl3): δ 167.9 
(C=O), 135.2 (C), 133.4 (C), 129.6 (2 x CH, Ar), 128.8 (2 x CH, Ar), 50.3 (CH2), 
49.3 (CH2), 47.3 (CH2), 43.2 (CH2).  
4.2.2.3. 1-(4-Methoxybenzyl)-piperazin-2-one (4c)    
Synthesised according to the general procedure using 4-(4-methoxybenzyl)-3-oxo-
piperazine-1-carboxylic acid tert-butyl ester 3c (0.46 g, 2.08 mmol). Yield: 70% as 
yellow crystals, m.p: 60-64 °C. 1H-NMR (CDCl3): δ 7.20 (d, J = 8.7 Hz, 2H, Ar), 6.86 
(d, J = 8.7 Hz, 2H, Ar), 4.54 (s, 2H, CH2), 3.80 (s, 3H, CH3), 3.58 (s, 2H, CH2), 3.20 
(t, J = 5.5 Hz, 2H, CH2), 3.02 (t, J = 5.5 Hz, 2H, CH2), 1.85 (s, 1H, NH). 
13C-NMR 
(CDCl3): δ 167.7 (C=O), 159.1 (C), 129.6 (2 x CH, Ar), 129.4 (C), 114.0 (2 x CH, 
Ar), 55.3 (CH3), 50.4 (CH2), 49.2 (CH2), 47.0 (CH2), 43.2 (CH2). 
4.2.2.4. 1-(2,4-Dichlorobenzyl)-piperazin-2-one (4d) 
Synthesised according to the general procedure using 4-(2,4-dichlorobenzyl)-3-oxo-
piperazine-1-carboxylic acid tert-butyl ester 3d  (0.76 g, 2.1 mmol). Yield: 72% as an 
orange coloured solid, m.p: 96-102 °C. 1H-NMR (CDCl3): δ 7.39 (d, J = 1.95 Hz, 1H, 
Ar), 7.25 (m, 2H, Ar), 4.71 (s, 2H, CH2), 3.57 (s, 2H, CH2), 3.27 (t, J = 5.5Hz, 2H, 
CH2), 3.08 (t, J = 5.2 Hz, 2H, CH2). 
13C-NMR (CDCl3): δ 168.1 (C=O), 134.4 (C), 
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133.9 (C), 132.8 (C), 130.4 (CH, Ar), 129.3 (CH, Ar), 127.5 (CH. Ar), 50.3 (CH2), 
47.9 (CH2), 46.7 (CH2), 43.2 (CH2). 
4.2.3. General methods for synthesis of 4-(bromopropyl)-1-(4-substituted-benzyl)-
piperazin-2-one (5) 
Method 1: To a solution of 1-(4-substituted-benzyl)-piperazin-2-one 4 (1 eq) in 
anhydrous acetone (10 mL/1.5 mmol) were added K2CO3 (3 eq) and dibromopropane 
(4 eq). The reaction mixture was stirred at room temperature for 4 days. The reaction 
mixture was filtered and the filtrate was evaporated.  The formed residue was extract 
with CH2Cl2 (100 mL) and washed with water (50 mL). The organic layer was dried 
(MgSO4), evaporated under reduced pressure and purified by flash chromatography 
using CH2Cl2:CH3OH gradient elution. 
Method 2: To a cooled (0 oC) solution of 1-(4-substituted-benzyl)-piperazin-2-one 4 
(1 eq) in anhydrous acetone (10 mL /1.5 mmol) was added LiHMDS (1.2 eq) and the 
reaction stirred at 0 °C for 1 h. Dibromopropane (2 eq) was added to the mixture and 
the reaction stirred at room temperature for 48 h.  The solvent was evaporated and the 
residue extracted with CH2Cl2 (100 mL), washed with 2M aqueous NaHCO3 (50 mL) 
and water (50 mL). The organic layer was dried (MgSO4), evaporated under reduced 
pressure and purified by flash chromatography using CH2Cl2:CH3OH gradient 
elution. 
4.2.3.1. 4-(3-Bromopropyl)-1-(4-fluorobenzyl)-piperazin-2-one (5a) 
Synthesised according to method 2 using 1-(4-fluorobenzyl)-piperazin-2-one 4a (0.21 
g, 1.05 mmol). Yield: 75% as an orange liquid. 1H-NMR (CDCl3): δ 7.24 (m, 2H, Ar), 
7.00 (m, 2H, Ar), 4.55 (s, 2H, CH2), 3.46 (t, J = 6 .4 Hz, 2H, CH2), 3.22  (t, J = 5.9 
Hz, 2H, CH2), 3.21 (s, 2H, CH2), 2.65 (t, J = 5.4 Hz, 2H, CH2), 2.54 (t, J = 6.8 Hz, 
2H, CH2), 2.01 (m, 2H, CH2). 
13C-NMR (CDCl3): δ 167.0 (C=O), 163.2, 132.3 (C-F), 
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129.9 (2 x CH-Ar) 119.0 (C), 115.4 (CH, Ar), 115.4 (CH, Ar), 57.3 (CH2), 55.3 
(CH2), 49.9 (CH2), 49.1 (CH2), 45.9 (CH2), 31.2 (CH2), 29.7 (CH2). [ES-HRMS] 
calculated for C14H18BrFN2O: 330.0566 [M+H]
+. Found: 330.0566 [M+H]+. 
4.2.3.2. 4-(3-Bromopropyl)-1-(4-chlorobenzyl)-piperazin-2-one (5b)  
Synthesised according to method 1 using 1-(4-chlorobenzyl)-piperazin-2-one 4b (0.17 
g, 0.76 mmol). Yield: 42% as a yellow oil. 1H-NMR (CDCl3): δ 7.29 (d, J = 8.45 Hz, 
2H, Ar), 7.20 (d, J = 8.45 Hz, 2H, Ar), 4.55 (s, 2H, CH2), 3.46 (t, J = 6.5 Hz, 2H, 
CH2), 3.22 (s, 2H, CH2), 3.21 (t, J = 5.5 Hz, 2H, CH2), 2.65 (t, J = 5.5 Hz, 2H, CH2), 
2.55 (t, J = 6.8 Hz, 2H, CH2), 2.01 (m, 2H, CH2). 
13C-NMR (CDCl3): δ 166.9 (C=O), 
135.1 (C), 133.4 (C), 128.8 (2 x CH, Ar), 129.6 (2 x CH, Ar), 57.3 (CH2), 55.3 (CH2), 
49.9 (CH2), 48.8 (CH2), 46.0 (CH2), 31.2 (CH2), 29.7 (CH2). [ES-HRMS] calculated 
for C14H18BrClN2O: 344.0291 [M]
+. Found: 344.0283 [M]+. 
4.2.3.3. 4-(3-Bromopropyl)-1-(4-methoxybenzyl)-piperazin-2-one (5c)  
Synthesised according to method 1 using 1-(4-methoxybenzyl)-piperazin-2-one 4c 
(0.37 g, 1.67 mmol). The residue was purified by flash chromatography with 
EtOAc:CH3OH: gradient elution. Yield: 69% as a colourless oil. 
1H-NMR (CDCl3): δ 
7.20 (d, J = 8.7 Hz, 2H, Ar), 6.87 (d, J = 8.7 Hz, 2H, Ar), 4.54 (s, 2H, CH2), 3.81 (s, 
3H, OCH3), 3.81 (s, 2H, CH2), 3.23 (m, 4H, 2 x CH2), 2.66 (t, J = 5.5 Hz, 2H, CH2), 
2.56 (t, J = 6.8 Hz, 2H, CH2), 2.03 (dt, J = 6.6, 13.2 Hz, 2H, CH2). 
13C-NMR (CDCl3): 
δ 166.6 ( C=O ), 159.1 (C), 129.6 (2 x CH, Ar), 128.6 (C), 114.1 (2 x CH, Ar), 57.3 
(CH2), 55.4 (CH2), 55.3 (OCH3), 50.0 (CH2), 48.9 (CH2), 45.6 (CH2), 31.2 (CH2), 
29.7 (CH2). [ES-HRMS] calculated for C15H21BrN2O2: 340.0786 [M]
+. Found: 
340.0786 [M]+ . 
4.2.3.4. 4-(3-Bromopropyl)-1-(2,4-dichlorobenzyl)-piperazin-2-one (5d)  
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Synthesised according to method 1 using 1-(2,4-dichlorobenzyl)-piperazin-2-one 4d  
(0.27 g, 1.04 mmol). Yield: 61% as a yellow viscous oil. 1H-NMR (CDCl3): δ 7.41 (t, 
J = 1.1 Hz, 1H, Ar), 7.25 (m, 2H, Ar), 4.71 (s, 2H, CH2), 3.49 (t, J = 6.5 Hz, 2H, 
CH2), 3.30 (t, J = 5.5 Hz, 2H, CH2), 3.25 (s, 2H, CH2), 2.72 (t, J = 5.5 Hz, 2H, CH2), 
2.59 (t, J = 6.8 Hz, 2H, CH2), 2.05 (dt, J = 6.6, 13.3 Hz, 2H, CH2). 
13C-NMR (CDCl3): 
δ 167.2 (C=O), 134.4 (C), 133.9 (C), 132.7 (C), 130.4 (CH, Ar), 129.4 (CH, Ar), 
127.6 (CH, Ar), 57.4 (CH2), 55.4 (CH2), 50.0 (CH2), 46.6 (CH2), 46.4 (CH2), 31.1 
(CH2), 29.7 (CH2). 
4.2.4. General methods for synthesis of 4-(3-imidazol-1-yl-propyl)-1-(substituted)-
piperazin-2-one (6) 
To a solution of NaH (2 eq) in dry DMF (10 mL/2 mmol of 5), imidazole (2 eq) was 
added, the reaction was stirred for 1 h at 30 °C then cooled to room temperature. 4-
(Bromoalkyl)-1-(4-substituted-benzyl)-piperazin-2-one (5) (1 eq) was added to the 
reaction mixture and left stirring overnight at 45 °C.  Water (3 mL) was added to 
quench excess NaH and the reaction was evaporated under reduced pressure. Water 
(50 mL) was added to the formed residue and the product was extracted with ethyl 
acetate (3 x 50 mL). The organic layers were combined and washed with water (50 
mL). The organic layer was then dried (MgSO4), evaporated under reduced pressure 
and purified by preparative TLC, using EtOAc : CH3OH 5:1 v/v as eluent. 
4.2.4.1. 4-(3-(1H-imidazol-1-yl)propyl)-1-(4-fluorobenzyl)piperazin-2-one (6a)  
Synthesised according to the general procedure using 5a (0.15 g, 0.45 mmol) Yield: 
48% as a yellow oil. 1H-NMR (CDCl3): δ 7.47 (s, 1H, imidazole), 7.24 (m, 2H, Ar), 
7.06 (s, 1H, imidazole), 7.02 (m, 2H, Ar), 6.90 (s, 1H, imidazole), 4.5 (s, 2H, CH2), 
4.04 (t, J = 6.7 Hz, 2H, CH2), 3.23 (t, J = 5.4 Hz, 2H, CH2), 3.19 (s, 2H, CH2), 2.61 (t, 
J = 5.4 Hz, 2H, CH2), 2.34 (t, J = 6.6 Hz, 2H, CH2), 1.94 (m, 2H, CH2). 
13C-NMR 
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(CDCl3): δ 166.7 (C=O), 163.3 (C-F), 161.3 (C-F), 137.3 (CH, imidazole), 132.3 (C), 
129.9 (2 x CH-Ar), 129.5 (CH, imidazole), 118.8 (CH, imidazole), 115.5 (2 x CH, 
Ar), 57.1 (CH2), 53.6 (CH2), 50.0 (CH2), 48.8 (CH2), 45.8 (CH2), 44.2 (CH2), 27.9 
(CH2). [ES-HRMS] calculated for C17H21FN4O: 316.1699 [M+H]
+. Found: 316.1694 
[M+H]+. 
4.2.4.2. 4-(3-(1H-imidazol-1-yl)propyl)-1-(4-chlorobenzyl)piperazin-2-one (6b)  
Synthesised according to the general procedure using 5b (0.11 g, 0.32 mmol). Yield: 
22% as a yellow oil. 1H-NMR (CDCl3): δ 7.40 (s, 1H, imidazole), 7.32 (d, J = 7.5 Hz, 
2H, Ar), 7.22 (d, J = 9.0 Hz, 2H, Ar), 7.07 (s, 1H, imidazole), 6.91 (s, 1H, imidazole), 
5.31 (s, 2H, CH2), 4.58 (s, 2H, CH2), 4.04  (t, J = 7.0 Hz, 2H, CH2), 3.24 (t, J = 6.0 
Hz, 2H, CH2), 2.61 (t, J = 5.5 Hz, 2H, CH2), 2.34 (t, J = 7.0 Hz, 2H, CH2), 1.94 (m, 
2H, CH2). 
13C-NMR (CDCl3): δ 166.7 (C=O), 135.0 (C), 133.5 (C), 129.7 (2 x CH, 
Ar), 129.6 (CH, imidazole), 129.0 (CH, imidazole), 128.9 (2 x CH, Ar), 118.5 (CH, 
imidazole), 57.1 (CH2), 53.6 (CH2), 50.0 (CH2), 48.9 (CH2), 45.9 (CH2), 44.2 (CH2), 
27.9 (CH2). [ES-HRMS] calculated  for C17H21ClN4O: 332.1404 [M+H]
+. Found: 
332.1410 [M+H]+. 
4.2.4.3. 4-(3-(1H-imidazol-1-yl)propyl)-1-(4-methoxybenzyl)piperazin-2-one (6c)  
Synthesised according to the general procedure using 5c (0.33 g, 0.97 mmol). Yield: 
57% as a yellow liquid. 1H-NMR (DMSO-d6): δ 7.46 (s, 1H, imidazole), 7.20 (d, J = 
8.7 Hz, 2H, Ar), 7.06 (s, 1H, imidazole), 6.90 (s, 1H, imidazole), 6.87 (d, J = 8.7 Hz, 
2H, Ar), 4.54 (s, 2H, CH2), 4.03 (t, J = 6.7 Hz, 2H, CH2), 3.8 (s, 3H, CH3), 3.22 (t, J = 
5.5 Hz, 2H, CH2), 3.18 (s, 2H, CH2), 2.5 (t, J = 5.4 Hz, CH2), 2.32 (t, J = 6.7 Hz, 2H, 
CH2), 1.93 (m, , 2H, CH2). 
13C-NMR (DMSO-d6): δ 166.6 ( C=O), 159.0 (C, Ar), 
129.6 (2 x CH, Ar), 128.5 (C, Ar), 118.8 (CH-imidazole), 114.1 (2 x CH, Ar), 113.7 
(CH, imidazole), 110.6 (CH, imidazole), 57.1 (CH2), 55.3 (OCH3), 53.6 (CH2), 50.1 
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(CH2), 48.9 (CH2), 45.6 (CH2), 44.2 (CH2), 27.9 (CH2). [ES-HRMS] calculated for  
C18H24N4O2: 328.1899 [M+H]
+, Found: 328.1901 [M+H]+. 
4.2.4.4. 4-(3-(1H-imidazol-1-yl)propyl)-1-(2,4-dichlorobenzyl)piperazin-2-one (6d)  
Synthesised according to the general procedure using 5d (0.27 g, 0.71 mmol). Yield: 
51% as a yellow viscous oil. 1H-NMR (CDCl3): δ 7.07 (s, 1H, imidazole), 7.53 (s, 1H, 
imidazole), 7.40 (d, J = 1.2 Hz, 1H, Ar), 7.25 (m, 2H, Ar), 6.92 (s, 1H, imidazole), 
4.71 (s, 2H, CH2), 4.06 (t, J = 6.7 Hz, 2H, CH2), 3.29 (t, J = 5.4 Hz, 2H, CH2), 3.21 
(br.s, 2H, CH2), 2.65 (t, J = 5.4 Hz, 2H, CH2), 2.36 (t, J = 6.7 Hz, 2H, CH2), 1.96 (dt, 
J = 6.7, 13.4 Hz, 2H, CH2). 
13C-NMR (CDCl3): δ 167.0 (C=O), 137.2 (CH, 
imidazole), 134.3 (C), 133.9 (C), 132.6 (C), 130.3  (CH Ar), 129.3 (CH, Ar), 129.0 
(CH, imidazole), 127.5 (CH, Ar), 118.9 (CH, imidazole), 57.0 (CH2), 53.5 (CH2), 
49.9 (CH2), 46.5 (CH2), 46.4 (CH2), 44.3 (CH2), 27.8 (CH2). [ES-HRMS] calculated 
for C17H20Cl2N4O: 366.1014 [M+H]
+. Found: 366.1021 [M+H]+. 
 
4.2.5. General method for the synthesis of 2-imidazol or triazol-1-yl-1-[(substituted-
benzyl)piperazin-1-yl]ethanone (10) 
To a stirred suspension of potassium carbonate (4 eq) in dry CH3CN (10 mL/5 mmol 
of 9), imidazole or 1,2,4-triazole (4 eq) was added. The mixture was heated under 
reflux for 1 h at 45 °C and monitored using TLC system CH3OH:EtOAc 1:4 v/v. The 
reaction was cooled to room temperature then the crude 1-(substituted-benzyl-
piperazin-1-yl)-2-chloroethanone 9 (1eq) was added. The reaction was heated under 
reflux at 70 °C overnight. The solvent was evaporated, then water (30 mL) was added 
and then extracted with CH2Cl2 (3 x 30 mL). The organic layer was dried (MgSO4), 
evaporated under reduced pressure and purified by preparative TLC using CH3OH: 




Synthesized using 2-chloro-1-[4-(2,4-dichlorobenzyl)-piperazin-1-yl]-ethanone (0.6 g, 
1.8 mmol). Yield: 32% as a pale yellow solid, m.p: 70-74 ° C. 1H-NMR (CDCl3): δ 
8.25 (s, 1H, triazole), 7.97 (s, 1H, triazole), 7.42 (d, J = 2.1 Hz, 1H, Ar), 7.40 (d, J = 
2.1 Hz, 1H, Ar), 7.25 (dd, J = 2.1, 8.3 Hz, 1H, Ar), 5.06 (s, 2H, CH2CO), 3.68 (app.s, 
2H, CH2-piperazine), 3.64 (s, 2H, PhCH2), 3.58 (app.s, 2H, CH2-piperazine), 2.55 (m, 
4H, 2 x CH2- piperazine). 
13C-NMR (CDCl3): δ 163.6 (C=O), 151.7 (CH, triazole), 
144.7 (CH, triazole), 135.1 (2 x C), 133.8 (C), 131.6 (CH, Ar), 129.4 (CH, Ar), 127.1 
(CH, Ar), 58.4 (CH2), 52.7 (CH2), 52.3 (CH2), 50.4 (CH2), 45.3 (CH2), 42.3 (CH2). 
[APCI-HRMS] calculated for C15H17C12N5: 354.0888 [M+H]
+. Found: 354.0890 
[M+H] +.  
4.2.5.2. 1-(4-(4-Fluorobenzyl)piperazin-1-yl)-2-(1H-1,2,4-triazol-1-yl)ethanone (10b) 
Synthesized using 2-chloro-1-[4-(4-fluorobenzyl)piperazin-1-yl]ethanone (0.2 g, 0.7 
mmol). Yield: 35% as a yellow solid, m.p: 116-120 °C. 1H-NMR (CDCl3): δ 8.25 (s, 
1H, triazole), 7.95 (s, 1H, triazole), 7.30 (m, 2H, Ar), 7.02 (m, 2H, Ar), 5.06 (s, 2H, 
CH2CO), 3.67 (t, J = 4.5 Hz, 2H, CH2-piperazine), 4.56 (t, J = 4.7 Hz, 2H, CH2-
piperazine), 3.52 (s, 2H, PhCH2), 2.47 (m, 4H, 2 x CH2-piperazine). 
13C-NMR 
(CDCl3): δ 163.6 (C=O), 163.2, 161.3 (C-F), 151.7 (CH, triazole), 144.8 (CH, 
triazole), 130.7 (CH, Ar), 130.7 (CH, Ar), 115.4 (CH, Ar), 115.2 (CH, Ar), 62.1 
(CH2), 52.6 (CH2), 52.2 (CH2), 50.4 (CH2), 45.2 (CH2), 42.2 (CH2). [APCI- HRMS] 
calculated for C15H18FN5O: 304.1574 [M+H]
+. Found: 304.1561 [M+H] +.  
4.2.5.3. 1-(4-(4-Fluorobenzyl)piperazin-1-yl)-2-(1H-imidazol-1-yl)ethanone (10c) 
Synthesized using 2-chloro-1-[4-(4-fluorobenzyl)-piperazin-1-yl]-ethanone (0.2 g, 0.7 
mmol). Yield: 36% as a yellow oil. 1H-NMR (CDCl3): δ 7.51(s, 1H, imidazole), 7.28 
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(m, 2H, Ar), 7.08 (s, 1H, imidazole), 7.03 (m, 2H, Ar), 6.9 (s, 1H, imidazole), 4.77 (s, 
2H, CH2CO), 3.64 (br.s, 2H, CH2-piperazine), 3.57 (s, 2H, PhCH2), 3.45 (br.s, 2H, 
CH2-piperazine), 2.43 (br.s, 4H, 2 x CH2-piperazine).
 13C-NMR (CDCl3):δ 164.5 
(C=O), 163.1, 161.2 (C-F), 138.0 (CH, imidazole), 133.1 (C), 130.6 (2 x CH, Ar), 
129.1 (CH, imidazole), 120.2 (CH, imidazole), 115.2 (CH, Ar), 115.1 (CH, Ar), 61.97 
(CH2), 52.6 (CH2), 52.4 (CH2), 48.0 (CH2), 45.1 (CH2), 42.3 (CH2). [APCI-HRMS] 
calculated for C16H19FN4O: 303.1621[M+H]




4.2.6. General procedure for the synthesis of ethyl 1,4-bis(substituted 
benzyl)piperazine-2-carboxylate (14) 
2,3-Dibromopropionic acid ethyl ester (1.04 eq) was added dropwise to a solution of 
diamine 13 (1 eq) in hot dry toluene at 80 °C (70 mL/24 mmol of 13) and 
triethylamine (2.5 eq). The reaction mixture was refluxed overnight then the reaction 
was cooled, washed with saturated aqueous NaHCO3 (3 x 25 mL) and brine (2 x 25 
mL). The organic layer was dried (MgSO4), concentrated under reduced pressure and 
purified by flash chromatography gradient elution with CH2Cl2:CH3OH. The pure 
product appeared at 1-2 % methanol, unless otherwise indicated. 
4.2.6.1. Ethyl 1,4-dibenzylpiperazine-2-carboxylate (14a)27  
Synthesised according to the general procedure using N,N’-dibenzylethylendiamine 
13a (3.9 g, 16.33 mmol). Yield: 54% as a yellow oil. 1H-NMR (CDCl3): δ 7.33 (m, 
8H, Ar), 7.28 (m, 2H, Ar), 4.21 (q, J = 3.5 Hz, 2H, CH2CH3), 3.96 (d, J = 13.3 Hz, 1H, 
CH2Ph), 3.66 (m, 1H, CH2Ph), 3.60 (d, J = 13.2 Hz, 1H, CH2Ph), 3.49 (d, J = 13.2 Hz, 
1H, CH2Ph), 3.37 (m, 1H, CH-piperazine), 3.13 (m, 1H, piperazine), 2.86 (m, 1H, 
piperazine), 2.66 (d, J = 9.1 Hz, 1H, piperazine), 2.5 (m, 3H, piperazine), 1.32 (t, J = 
7.1 Hz, 3H, CH2CH3). 
13C-NMR (CDCl3): δ 172.1 (C, C=O), 138.3 (C, Ar), 138.0 (C, 
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Ar), 129.0 (2 x CH, Ar), 128.8 (2 x CH, Ar), 128.6 (2 x CH, Ar), 128.5 (2 x CH, Ar), 
127.5 (2 x CH, Ar), 62.8 (CH), 62.7 (CH2), 60.4 (CH2), 59.7 (CH2), 55.5 (CH2), 53.1 
(CH2), 48.6 (CH2), 14.3 (CH3). 
4.2.6.2. Ethyl 1,4-bis(4-methoxybenzyl)piperazine-2-carboxylate (14b)  
Synthesised according to the general procedure using N,N'-bis(4-
methoxybenzyl)ethane-1,2-diamine 13b (2 g, 6.6 mmol). Yield: 73% as an orange oil. 
1H-NMR (CDCl3): δ 7.25 (d, J = 9.0 Hz, 2H, Ar), 7.21 (d, J = 7.5 Hz, 2H, Ar), 6.85 
(m, 4H, Ar), 4.19 (q, J = 7.1 Hz, 2H, CH2CH3), 3.88 (d, J = 13.1 Hz, 1H, CH2Ph), 3.78 
(s, 6H, 2 x OCH3), 3.51 (d, J = 13.0 Hz, 2H, CH2Ph), 3.68 (d, J = 13.0 Hz, 1H, 
CH2Ph), 3.29 (m, 1H, piperazine), 3.05 (m, 1H, piperazine), 2.69 (s, 1H, piperazine), 
2.63 (s, 1H, piperazine), 2.48 (m, 2H, piperazine), 2.39 (m, 1H, piperazine), 1.26 (t, J 
= 7.1, 3H, CH2CH3). 
13C-NMR (CDCl3): δ 172.0 (C=O), 158.8 (C, 2 x C-OCH3), 
130.5 (2 x CH, Ar), 130.3 (2 x CH, Ar), 113.8 (4 x CH, Ar), 62.7 (CH), 61.9 (CH2), 
60.6 (CH2), 58.9 (CH2), 55.3 (2 x OCH3), 55.2 (CH2), 55.1 (CH2), 52.7 (CH2), 14.3 
(CH3). [ES-HRMS] calculated  for C23H31N2O4: 399.2284 [M+H]
+. Found: 399.2270 
[M+H]+. 
4.2.6.3. Ethyl 1,4-bis(3,5-dimethoxybenzyl)piperazine-2-carboxylate  (14c)  
 Synthesised according to the general procedure using N,N'-bis(3,5-
dimethoxybenzyl)ethane-1,2-diamine 13c (1.5 g, 4.1 mmol). Yield: 68% as an orange 
solid, m.p. 58-60 °C. 1H-NMR (CDCl3): δ 6.53 (d, J = 2.1 Hz, 2H, Ar), 6.49 (d, J = 2.1 
Hz, 2H, Ar), 6.37 (m, 2H, Ar), 4.20 (q, J = 7.1 Hz, 2H, CH2CH3), 3.88 (d, J = 13.5 Hz, 
1H, PhCH2), 3.797 (s, 6H, 2 x OCH3), 3.791 (s, 6H, 2 x OCH3), 3.61 (m, 1H, CH-
piperazine), 3.52 (d, J = 13.5 Hz, 1H,CH2Ph), 3.37 (d, J = 13.6 Hz, 2H, CH2Ph), 3.15 
(m, 1H, piperazine), 2.82 (m, 1H, piperazine), 2.59 (m, 2H, piperazine), 2.47 (m, 2H, 
piperazine), 1.25 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C-NMR (CDCl3): δ 172.1 (C, C=O), 
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160.8 (4 x C, C-OCH3), 140.8 (C, Ar), 140.6 (C, Ar), 106.8 (4 x CH, Ar), 99.1 (CH, 
Ar), 99.0 (CH, Ar), 62.7 (CH2), 62.4 (CH), 60.3 (CH2), 59.6 (CH2), 55.5 (CH2), 55.3 
(4 x OCH3), 53.2 (CH2), 48.5 (CH2), 14.2 (CH3). [AP-HRMS] calculated for 
C25H35N2O6: 459.2495 [M+H]
+. Found: 459.2475 [M+H]+.  
4.2.7. General procedure for the synthesis of [1,4-bis(substituted benzyl)piperazin-
2-yl]methanol (15) 
A suspension of LiAlH4 (4 eq, 1M in Et2O) was diluted with dry Et2O (15 mL/11 
mmol LiAlH4) then added to a solution of 1,4-bis(substituted-benzyl)piperazine-2-
carboxylic acid ethyl ester 14 (1 eq) in dry Et2O (20 mL/6 mmol of 14) slowly over 1 
h at 0 oC. The reaction was stirred overnight at room temperature, cooled to 0 oC and 
treated carefully with saturated aqueous NaHCO3 until cessation of effervescence. 
The solution was extracted with ethyl acetate (3 x 50 mL), the organic layer was dried 
(MgSO4), concentrated under reduced and purified by flash chromatography using 
gradient elution CH2Cl2:CH3OH, and the product appeared at 2% methanol. 
4.2.7.1. 1,4-Dibenzylpiperazin-2-yl-methanol (15a)28 
Synthesised according to the general procedure using 1,4-dibenzylpiperazine-2-
carboxylic acid ethyl ester  14a (3.1 g, 9.1 mmol). Yield: 92% as a yellow oil. 1H-
NMR (CDCl3): δ 7.35 (m, 8H, Ar), 7.28 (m, 2H, Ar), 4.05 (dd, J = 2.5 Hz, 10.9 Hz, 
2H, CH2), 3.65 (dd, J = 2.6, 11.2 Hz, 1H), 3.43 (s, 2H, CH2), 3.50 (d, J = 13.5 Hz , 
1H), 2.97 (m, 1H, piperazine), 2.76 (dd, 2.6, 10.8 Hz, 1H, piperazine), 2.68 (m, 1H, 
piperazine), 2.58 (m, 2H,  piperazine), 2.48 (m, 1H, piperazine), 2.40 (m, 1H, 
piperazine). 13C-NMR (CDCl3): δ 138.5 (C, Ar), 137.6 (C, Ar), 129.2 (2 x CH, Ar), 
128.7 (2 x CH, Ar), 128.4 (2 x CH, Ar), 127.5 (2 x CH, Ar), 127.4 (2 x CH, Ar), 63.0 
(CH2), 62.1 (CH2), 58.5 (CH), 58.1 (CH2), 56.0 (CH2), 53.0 (CH2), 50.0 (CH2). 
4.2.7.2. 1,4-Bis(4-methoxybenzyl)piperazin-2-yl]methanol  (15b)29  
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Synthesised according to the general procedure using 1,4-bis(4-
methoxybenzyl)piperazine-2-carboxylic acid ethyl ester 14b (1.9 mL, 4.7 mmol). 
Yield: 62% as a beige solid, m.p: 94-96 °C. 1H-NMR (CDCl3): δ 7.22 (t, J = 8.0 Hz, 
2H, Ar), 6.85 (dd, J = 2.0, 9.0 Hz, 2H, Ar), 3.98 (m, 2H, CH2), 3.77 (s, 6H, 2 x 
OCH3), 3.75 (s, obscured 1H, CH2), 3.61 (m, 1H, CH2), 3.37 (m, 2H, CH2), 2.92 (m, 
1H, piperazine), 2.71-2.33 (m, 6H, piperazine). 13C-NMR (CDCl3): δ 158.8 (C, C-
OCH3), 158.7 (C, C-OCH3), 130.3 (2 x CH, Ar), 130.2 (C, Ar), 129.9 (2 x CH, Ar), 
129.7 (C, Ar), 114.0 (CH, Ar), 62.8 (CH2), 62.5 (CH2), 58.9 (CH), 57.8 (CH2), 56.1 
(CH2), 55.2 (CH3), 52.4 (CH2), 49.9 (CH2). 
4.2.7.3. [1,4-Bis(3,5-dimethoxybenzyl)piperazin-2-yl]methanol (15c)  
Synthesised according to the general procedure using 1,4-bis(3,5-
dimethoxybenzyl)piperazine-2-carboxylic acid ethyl ester 14c  (1.17g, 2.5 mmol). 
Yield: 50% as a yellow oil. 1H-NMR (CDCl3): δ 6.41 (d, J = 2.2 Hz, 2H, Ar), 6.39 (d, 
J = 2.2 Hz, 2H, Ar), 6.26 (m, 2 x CH, Ar), 3.90 (dd, J = 3.3, 11.3 Hz, 1H), 3.82 (d, J = 
13.1 Hz, 1H), 3.68 (s, 12H, 4 x OCH3), 3.35 (d, J = 13.5 Hz, 1H), 3.35 (m, 3H), 2.89 
(m, 1H, piperazine), 2.58 (m, 2H, piperazine), 2.60 (m, 1H, piperazine), 2.41 (m, 2H, 
piperazine), 2.33 (m, 1H, CH-piperazine). 13C-NMR (CDCl3): δ 160.9 (2 x C), 160.8 
(2 x C), 141.0 (C), 140.0 (C), 107.2 (2 x CH, Ar), 106.9 (2 x CH, Ar), 99.3 (CH, Ar), 
99.0 (CH, Ar), 63.2 (CH2), 62.1 (CH2), 58.9 (CH), 58.2 (CH2), 58.0 (CH2), 55.3 (4 x 
OCH3), 52.4 (CH2), 49.89 (CH2). [AP-HRMS] calculated for C23H33N2O5: 417.2389 
[M+H]+. Found: 417.2394 [M+H]+.  
4.2.8. General procedure for the synthesis of 1,4-Bis(substituted-benzyl)-2 
chloromethylpiperazine  (16) 
To 1,4-bis(substituted benzyl)piperazin-2-yl]-methanol 15 (1 eq)  in  dry  toluene (20 
mL/1 mmol of 15) was added SOCl2 (2 eq) slowly while cooling in an ice bath. The 
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reaction mixture was refluxed overnight at 80 °C then cooled to room temperature and 
washed with saturated aqueous NaHCO3 (3 x 30 mL), brine (2 x 20 mL) and water (2 
x 20 mL). The organic layer was dried (MgSO4) and concentrated under reduced 
pressure. 
4.2.8.1. 1,4-Dibenzyl-2-chloromethylpiperazine (16a) 
Synthesised according to the general procedure using (1,4-dibenzylpiperazin-2-
yl)methanol 15a (2 g, 6.7 mmol). The product was pure enough to proceed to the next 
step. Yield: 76% as a yellowish orange oil. 1H-NMR (CDCl3): δ 7.39 (m, 8H, Ar), 
7.31 (m, 2H, Ar), 3.96 (m, 2H, CH2), 3.76 (dd, J = 2.8, 11.1 Hz, 1H), 3.59 (d, J = 6 
Hz, 2H, CH2), 3.56 (d, J = 13.3 Hz, 1H), 2.92 (m, 1H, piperazine), 2.77 (m, 1H, 
piperazine), 2.70 (d, J = 4.2 Hz, 2H, piperazine), 2.52 (m, 1H, piperazine), 2.44 (d, J = 
7.4 Hz, 2H, piperazine). 13C NMR (CDCl3): δ 138.6 (C), 138.1 (C), 129.4 (2 x CH, 
Ar), 129.3 (2 x CH, Ar), 128.7 (2 x CH, Ar), 128.5 (2 x CH, Ar), 127.3 (2 x CH, Ar), 
62.9 (CH2), 62.0 (CH), 60.4 (CH2), 58.2 (CH2), 55.8 (CH2), 49.1 (CH2), 42.6 (CH2). 
4.2.8.2. 2-Chloromethyl-1,4-bis(4-methoxybenzyl)piperazine (16b)  
Synthesised according to the general procedure using 1,4-bis(4-
methoxybenzyl)piperazin-2-yl]methanol 15b (1 g, 2.8 mmol). Obtained as a white 
crystalline solid after recrystallisation from methanol. Yield: 31%, m.p. 76-82 °C. 1H-
NMR (CDCl3): δ 7.26 (m, 4H, Ar), 7.87 (m, 4H, Ar), 3.91 (m, 2H, CH2), 3.82 (s, 3H, 
OCH3), 3.81 (s, 3H, OCH3), 3.70 (dd, J = 2.6, 11.2 Hz, 1H), 3.50 (m, 2H, CH2), 3.42 
(d, J =13.1 Hz, 1H), 2.87 (m, 1H, piperazine), 2.73 (m, 1H, piperazine), 2.63 (m, 2H, 
piperazine), 2.50 (m, 1H, piperazine), 2.4 (d, J = 6.4 Hz, 2H, piperazine). 13C-NMR 
(CDCl3): δ 158.9 (C), 158.8 (C), 130.4 (2 x CH, Ar), 130.2 (2 x C), 130.0 (2 x CH, 
Ar), 113.9 (4 x CH, Ar), 62.1 (CH2), 59.9 (CH), 57.4 (CH2), 55.3 (CH3), 55.1 (CH2), 
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52.5 (CH2), 48.9 (CH2), 42.7 (CH2). [AP-HRMS] calculated  for C21H28ClN2O2: 
375.1839 [M+H]+. Found: 375.1831 [M+H]+.   
4.2.9. General procedure for the synthesis of 1,4-bis(substituted-benzyl)-2-imidazol-
1-ylmethyl-piperazine and  1,4-bis(substituted-benzyl)-2-[1,2,4]triazol-1-ylmethyl-
piperazine (17).  
To a solution of imidazole or triazole (4 eq) in dry DMF (5 mL/2.5 mmol of starting 
material) was added NaH (60% dispersion in mineral oil, 4 eq). After refluxing the 
mixture for 1 h at 40 oC, a solution of 1,4-bis(substituted-benzyl)-2-chloromethyl-
piperazine 16 (1 eq) in dry DMF (5 mL/2.5 mmol of 16) and KI (1.08 eq) was added 
to the mixture and refluxed overnight at 60 oC. The reaction was cooled, diluted with 
EtOAc (100 mL) and washed with brine (2 x 10 mL) and water (2 x 10 mL), the 
organic layer was dried (MgSO4), evaporated and the resulting residue was further 
purified. 
4.2.9.1. 1,4-Dibenzyl-2-imidazol-1-yl-methylpiperazine (17a)  
Synthesised according to the general procedure using 1,4-dibenzyl-2-
chloromethylpiperazine 16a (0.8 g, 2.5 mmol), imidazole (0.66 g, 10 mmol). The 
product was purified by flash chromatography using gradient elution of 
CH2Cl2:CH3OH, the product appeared at 2% methanol. Yield: 63% as a yellowish 
orange semi-solid. 1H-NMR (CDCl3): δ 7.32 (m, 8H, Ar), 7.25 (s, 1H, imidazole), 
6.96 (s, 1H, imidazole), 6.64 (s, 1H, imidazole), 4.30 (m, 1H), 4.15 (dd, J = 4.0, 13.7 
Hz, 1H), 3.89 (d, J = 13.4 Hz, 1H), 3.67 (dd, J = 5.0, 18.5 Hz, 1H), 3.53 (d, J = 12.8 
Hz, 1H), 3.37 (d, J = 12.8 Hz, 1H), 2.87 (m, 2H, piperazine), 2.56 (m, 2H, 
piperazine), 2.41 (m, 1H, piperazine), 2.3 (d, J = 3.4 Hz, 2H, piperazine). 13C-NMR 
(CDCl3): δ 138.3 (C, Ar), 138.3 (C, Ar), 137.6 (CH, imidazole), 129.8 (2 x CH, Ar), 
129.0 (CH, imidazole), 128.6 (2 x CH, Ar), 128.5 (2 x CH, Ar), 128.4 (2 x CH, Ar), 
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127.4 (2 x CH, Ar), 119.5 (CH, imidazole), 63.3 (2 x CH2), 58.5 (CH), 58.3 (2 x 
CH2), 52.5 (2 x CH2). [AP-HRMS] calculated for C22H27N4: 347.2236 [M+H]
+. 
Found: 347.2222 [M+H]+.   
4.2.9.2. 1,4-Dibenzyl-2-[1,2,4]triazol-1-yl-methylpiperazine (17b)  
Synthesised according to the general procedure using 1,4-dibenzyl-2-
chloromethylpiperazine 16a (0.8 g, 2.5 mmol), triazole (0.66 g, 10 mmol). The 
product was purified by flash chromatography using gradient elution of 
CH2Cl2:CH3OH, the product appeared at 2% methanol. Yield: 57% as a yellowish 
orange oil. 1H-NMR (CDCl3): δ 7.88 (s, 1H, triazole), 7.81 (s, 1H, triazole), 7.31 (m, 
10H, Ar), 4.54 (s, 1H), 4.47 (dd, J = 4.6, 13.6 Hz, 1H), 3.85 (d, J = 13.4 Hz, 1H), 3.75 
(d, J = 13.4 Hz, 1H), 3.58 (d, J = 11.0 Hz, 1H), 3.40 (d, J = 12.2 Hz, 1H), 3.18 (m, 
1H, piperazine), 2.85 (s, 1H, piperazine), 2.42 (s, 2H, piperazine), 2.57 (s, 2H, 
piperazine), 2.32 (d, J = 9.1 Hz, 1H, piperazine). 13C-NMR (CDCl3): δ 151.9 (CH, 
triazole), 143.8 (CH, triazole), 138.6 (2 x C), 129.3 (2 x CH, Ar), 128.8 (2 x CH, Ar), 
128.6 (2 x CH, Ar), 128.4 (2 x CH, Ar), 127.3 (2 x CH, Ar), 62.8 (2 x CH2), 58.3 (2 x 
CH2), 57.9 (CH), 52.3 (2 x CH2). [ES-HRMS] calculated for  C21H26N5: 348.4646 
[M+H]+. Found: 348.4638 [M+H]+.                                                                                                               
4.2.9.3. 1,4-Bis(4-methoxybenzyl)-2-[1,2,4]triazol-1-ylmethyl-piperazine (17c)  
Synthesised according to the general procedure using 2-chloromethyl-1,4-bis(4-
methoxybenzyl)piperazine   16b (0.31 g, 0.8 mmol), triazole (0.21 g, 3.2 mmol). The 
product was purified by preparative TLC using CH2Cl2: CH3OH 95:5 v/v as eluent. 
Yield: 36% as a yellowish orange oil. 1H-NMR (CDCl3): δ 7.88 (s, 2H, triazole), 7.20 
(d, J = 8.0 Hz, 2H, Ar), 7.18 (d, J = 8.6 Hz, 2H, Ar), 6.86 (m, 4H, Ar), 4.49 (d, J = 4.7 
Hz, 1H), 4.46 (dd, J = 4.7, 13.7 Hz, 1H), 3.82 (s, 3H, CH3), 3.80 (s, 3H, CH3), 3.78 
(obscured d, 1H), 3.66 (d, J = 5.0 Hz, 1H), 3.49 (d, J = 11.9 Hz, 1H), 3.35 (d, J = 12.7 
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Hz, 1H), 3.17 (m, 1H, piperazine), 2.85 (m, 1H, piperazine), 2.52 (d, J = 11.5 Hz, 2H, 
piperazine), 2.38 (d, J = 8.8 Hz, 2H, piperazine), 2.28 (dd, J = 3.7, 11.4 Hz, 1H, 
piperazine). 13C-NMR (CDCl3): δ 159.0 (C, C-OCH3), 158.8 (C, C-OCH3), 151.8 
(CH, triazole), 143.8 (CH, triazole), 132.0 (CH, Ar), 129.9 (2 x CH, Ar), 114.1 (4 x 
CH, Ar), 62.2 (2 x CH2), 57.8 (CH), 57.6 (2 x CH2), 55.3 (CH3), 55.3 (CH3), 52.0 (2 x 
CH2). [ES-HRMS] calculated for  C23H30N5O2: 408.2394 [M+H]
+. Found: 408.2385 
[M+H]+.                                                                                                               
4.2.9.4. 1,4-Bis(3,5-dimethoxybenzyl)2-imidazole-1-ylmethyl-piperazine (17d)  
To a solution of [1,4-bis(3,5-dimethoxybenzyl)-piperazin-2-yl]-methanol 15c (0.25 g, 
0.6 mmol) in dry CH2Cl2 (30 mL) was added methanesulfonylchloride (0.05 mL, 0.69 
mmol) and triethylamine (0.16 mL, 1.18 mmol) at 0 oC. The resulting mixture was 
stirred at room for 2 h. After quenching the reaction with water (20 mL), the organic 
phase was washed with water (2 x 20 mL), dried (MgSO4) and evaporated under 
vacuum. The resulting methane sulfonate derivative was added to a solution of 
imidazole sodium salt (prepared from imidazole (0.12 g, 1.7 mmol) and NaH 60% 
dispersion in mineral oil (0.04 g, 1.7 mmol) in dry toluene (20 mL), previously 
refluxed at 40 °C for 1h) and the reaction mixture refluxed overnight at 115 °C. The 
reaction was cooled to room temperature and washed with water (5 x 25 mL). The 
organic layer was separated, dried (MgSO4), evaporated under vacuum and purified 
by preparative TLC using CH2Cl2:CH3OH 98:2 v/v. Yield: 14% as an oily yellow 
orange solid. 1H-NMR (CDCl3): δ 7.25 (s, 1H, imidazole), 6.88 (s, 1H, imidazole), 
6.31 (s, 1H, imidazole), 6.42 (m, 4H, Ar), 6.31 (m, 2H, Ar), 4.21 (m, 1H), 4.11 (dd, J 
= 4.3, 13.8 Hz, 1H), 3.71 (s, 6H, 2 x OCH3), 3.70 (s, 6H, 2 x OCH3), 3.69 (d, J = 10.3 
Hz, 1H), 3.38 (m, 1H), 3.25 (d, J = 13.0 Hz, 2H), 2.81 (m, 1H, piperazine), 2.68 (m, 
1H, piperazine), 2.55 (m. 1H, piperazine), 2.48 (m, 2H, piperazine), 2.35 (m, 1H, 
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piperazine), 2.23 (m, 1H, piperazine). 13C NMR (CDCl3): δ 160.9 (2 x C), 160.85 (2 x 
C), 140.9 (C), 140.6 (C), 137.6 (CH, imidazole), 129.2 (CH, imidazole), 119.5 (CH, 
imidazole), 107.1 (2 x CH, Ar), 106.3 (2 x CH, Ar), 98.9 (CH, Ar), 98.8 (CH, Ar), 
60.4 (2 x CH2), 58.4 (CH), 58.1 (2 x CH2), 55.3 (4 x OCH3), 52.3 (2 x CH2). [ES-
HRMS] calculated for C26H35N4O4: 467.2653 [M+H]
+. Found: 467.2641 [M+H]+.   
4.3. Spectral Binding assay 
 CYP121A1 protein was expressed and purified as described previously.30 Ligand 
binding assays were performed by spectrophotometric titration using a Cary 60 UV-
visible scanning spectrophotometer (Agilent, UK) and a 1 cm path length quartz 
cuvette, recording spectra between 250 and 800 nm. Titrations were done with 3-4 
μM CYP121A1 at 28 oC in 100 mM potassium phosphate (KPi) buffer, 200 mM KCl, 
pH 7.85 with 0.004% Triton X-100. Ligand stocks solutions were prepared in 
dimethylsulfoxide (DMSO). Ligands were added in successive small volumes 
(typically 0.05-0.2 µL aliquots) from concentrated stock solutions to the protein in a 1 
mL final volume. Spectral measurements were taken before ligand addition, and 
following addition of each aliquot of ligand. Difference spectra at each stage in the 
titration were obtained by subtraction of the initial ligand-free enzyme spectrum from 
subsequent spectra collected after each addition of ligand. From the difference 
spectra, a pair of wavelengths were identified and defined as the absorbance 
maximum (Apeak) and minimum (Atrough). The overall absorbance change (Amax) was 
calculated by subtracting the minimum from the maximum absorbance for every 
spectrum collected after each aliquot addition. Graphs of (Amax, ΔΔAbsorbance) 
against [ligand] were plotted for each ligand. Titrations were repeated in triplicate and 
the final Kd value was determined from the average values across the three sets. The 
Kd values were determined from these plots of Absorbance against ligand 
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concentration, and by fitting the data using either a standard hyberbolic function 
(Equation 1) or the Hill equation (Equation 2) using Origin software (OriginLab, 
Northampton, MA).  
Aobs = (Amax*L/(Kd+L))                            (Equation 1) 
In Equation 1 (the standard hyperbolic function, essentially the Michaelis-Menten 
function adapted for ligand binding), Aobs is the observed absorbance change at ligand 
concentration L, Amax is the maximal absorbance change observed at ligand 
saturation, and Kd is the dissociation constant for the binding of the ligand (the 
substrate concentration at which Aobs = 0.5 x Amax). 
Aobs = (Amax × L
n)/(Kn+Ln)           (Equation 2) 
In equation 2 (the sigmoidal Hill equation), Aobs is the observed absorbance change at 
ligand concentration L, Amax is the absorbance change at ligand saturation, K is the 
apparent dissociation constant, and n is the Hill coefficient, a value describing the 
apparent extent of cooperativity observed in ligand binding. 
4.4. EPR Spectroscopy  
Continuous wave X-band EPR spectra of ligand-free CYP121A1 (110 μM) as well as 
for CYP121A1 in complex with compounds from Series A, B and C (2 mM) were 
recorded using a Bruker ELEXSYS E500 EPR spectrometer with an ER 4122SHQ 
Super High Q cavity. Temperature was controlled with an ESR900 cryostat (Oxford 
Instruments, Abingdon UK). Spectra were recorded at 10 K, microwave power at 0.5 
mW, modulation frequency 100 kHz and modulation amplitude at 7 G. Samples were 
prepared in 100 mM HEPES, 100 mM NaCl with 0.004% Triton X-100 at pH 7.6. 
Ligands were added from concentrated stock solutions in DMSO to a final 
concentration of 2 mM and samples incubated for 20 min at room temperature. 
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Samples were centrifuged briefly to remove any particulate matter prior to transfer to 
EPR tubes and freezing in liquid nitrogen. 
4.5. Antimycobacterial Activity Assay  
M. tuberculosis H37Rv was grown in 7H9 liquid medium with 10% OADC 
enrichment. The bacteria growth occurred at 37°C until reaching the mid-log phase 
(OD600nm=0.4-0.6). After this period, the bacterial suspensions were prepared as 
described below and REMA assays were performed. The anti-M. tuberculosis activity 
of the compounds  was determined by the REMA (Resazurin Microtiter Assay) 
method.20 Stock solutions of the tested compounds (10 µg/mL) were prepared in 
DMSO and diluted in Middlebrook 7H9 broth supplemented with 10% of OADC 
(OADC enrichment - BBL/Becton-Dickinson, Sparks, MD, USA). 
The microdilution of the compounds was performed in 96-well plates to obtain final 
compound concentration ranges of 0.39-100 µg/mL. Rifampicin in a concentration 
range of 0.004-1 µg/mL was added as control. Bacterial suspensions were prepared 
and their turbidities adjusted to match the optical density of McFarland no.1 standard. 
After further dilution of 1:20 in the respective Middlebrook 7H9 broth supplemented 
with OADC, 100 µL of the inoculum was added to each well of the 96-well plate. 
Cultures were incubated for 7 days at 37°C, and 30 µL of 0.01% resazurin were 
added. Wells were read after 24 h for colour change and measured as the fluorescence 
(excitation/emission of 530/590 nm filters respectively) in a microfluorimeter. The 
MIC was defined as the lowest concentration resulting in 90% inhibition of M. 
tuberculosis growth. The presented results are from two independent experiments. 
4.6. CYP121A1 Crystallography  
Untagged CYP121A1 protein and crystals were prepared as previously reported, with 
the following adaptations.30 Crystals were prepared using a Mosquito pipetting robot 
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(Molecular Dimensions, Newmarket, UK) in 800 nL drops with protein-to-mother 
liquor at a ratio of 1:1, by vapor diffusion in 1.5–2.1 M ammonium sulfate and 0.1 M 
sodium MES or Cacodylate from pH 5.5–6.15. Co-crystals were prepared following 
incubation with 2mM ligand prepared in DMSO. Protein solutions were centrifuged at 
14,000 rpm for 20 mins at 4 °C immediately before crystallogenesis. Ligand soaks 
were also carried out either by directly dissolving solid ligand at saturation or by the 
addition of a 2–5 mM ligand solution in DMSO to the mother liquor, and soaking was 
carried out for a minimum period of 24 h. Crystals were immersed in mother liquor 
supplemented with 10-30% oil as cryoprotectant and cryoprotected and flash-cooled 
in liquid nitrogen. Data were collected on beamline i02 (wavelength 0.9795 Å) at the 
Diamond Light Source Facility (Oxfordshire, UK). The diffraction data were reduced, 
scaled and merged using XDS31 or Xia232. Structures were refined using PHENIX33 
with the native CYP121A1 structure (PDB 1N40)30 as the starting model. Structural 
rebuilding and validation were performed with COOT,34 Molprobity35 and PDB 
REDO,36 Data collection and final refinement statistics are provided in Table 
3.  Images for presentation were rendered using an academic version of the PyMOL 
Molecular Graphics System, Schrödinger, LLC. 
4.7. Molecular modeling.  
4.7.1. Flexible alignment  
Ligands 17 and the natural substrate cYY were built using MOE14 builder, and saved 
in a database. Each ligand and cYY were extracted from the database and energy 
minimisation was performed using the MMFF94 forcefield.
 
Flexible alignment was 
performed for each ligand with cYY, giving an output database. The score functions 
were given for each pair that quantifies the quality of the alignment in terms of both 
internal strain and overlap of molecular features.  
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4.7.2. Docking studies  
Docking studies were performed on an Intel Xenon ® CPU E5462 @ 280GHz x 4 
processors running Linux Ubuntu 12.04.1 LTS using molecular operating 
environment (MOE) software14 and Mtb CYP121A1 co-crystallized with the natural 
substrate cYY at a resolution of 1.4 Å (PDB ID: 3G5H). All minimisations were 
performed with MOE to a RMSD gradient of 0.01 Kcal/mol/Å with MMFF94 
forcefield, and partial charges were automatically calculated. The charge of the heme 
iron at physiological pH was set to 3+ (geometry d2sp3) through the atom manager in 
MOE. The Alpha Triangle placement, which derives poses by random superposition 
of ligand atom triplets through alpha sphere dummies in the receptor site, was chosen 
to determine the poses. The London G scoring function estimates the free energy of 
binding of the ligand from a given pose. Refinement of the results using MMFF94 
forcefield, and rescoring of the refined results using the London G scoring function 
was applied. The output database dock file was created with different poses for each 
ligand and arranged according to the final score function (S), which is the score of the 
last stage that was not set to zero.  
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